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ABSTRACT
Fascioliasis, caused by the liver fluke Fasciola hepatica, is an infection that occurs worldwide, although
humans are accidental hosts. F. hepatica infection comprises two stages, hepatic and biliary, with
different signs and symptoms. Stool examination and ELISA can be used for the initial diagnosis.
Radiographic techniques, such as computerised tomography and ultrasonography, as well as magnetic
resonance imaging, are used widely for confirmation and follow-up of the disease. Invasive techniques,
such as percutaneous cholangiography, endoscopic retrograde cholangiography and liver biopsy, may
aid in the diagnosis but are not essential. Triclabendazole is recommended as the first-line agent for the
treatment of F. hepatica infection, with bithionol as an alternative.
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Fasciola hepatica is a trematode liver fluke that
infects primarily sheep, goats and cattle. The adult
fluke is large, flat, brownish and leaf-shaped, and
measures c. 2.5 · 1 cm. Large (140 · 75 lm) oval,
yellow–brown, operculated eggs are excreted in
the faeces of infected animals and hatch into
ciliated miracidia in water. To be infective, the
miracidium must first find its intermediate host,
which is a freshwater snail. Multiplication takes
place within the snail, and cercariae with unforked
tails emerge. The cercariae encyst on aquatic
vegetation and develop into the metacercarial
stage. The metacercaria are then ingested by either
normal hosts (sheep or cattle) or accidental hosts
(humans). The metacercariae excyst in the intes-
tine, perforate the intestinal wall, enter the peri-
toneum, and then pass through the liver capsule to
enter the biliary tree. In the biliary tract, the
mature fluke releases eggs, which are once again
excreted in faeces to complete the life-cycle [1].
Human fascioliasis occurs worldwide, and
there are significant numbers of patients in eastern
Europe, Iran, northern Africa and South America
[2]. F. hepatica infection has two different stages
with quite different signs and symptoms. The
hepatic (first, acute or invasive) stage of the illness
occurs when the organism perforates the liver and
begins to migrate through the liver parenchyma
towards the biliary radicles. The onset of this
stage occurs 1–3 months following ingestion of
metacercariae. Fever, urticaria, pain in the right
hypochondrium, hepatomegaly, hypergamma-
globulinaemia and marked eosinophilia are the
classical signs and symptoms of this stage. Mild
hepatitis, severe subcapsular haemorrhage and
frank hepatic necrosis can also be observed. A
combination of the symptoms of absolute eosino-
philia, fever and right upper quadrant pain should
bring to mind the possibility of F. hepatica infec-
tion. The second or biliary stage usually presents
with intermittent right upper quadrant pain with
or without cholangitis or cholestasis. Eosinophilia
can also be detected [3–5].
There are many different methods for the diag-
nosis of F. hepatica infection. Stool examination for
ova and parasites can be used, but is often unre-
vealing during the first stage. The method used
most widely for diagnosis is an ELISA that detects
antibodies against excretory–secretory antigen
products from adult F. hepatica [6,7]. This assay
has been shown to be rapid, sensitive and quanti-
tative. Radiographic techniques such as compu-
terised tomography (CT) and ultrasonography
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(US) are also used widely to aid and confirm the
diagnosis. CT and US may also be used in follow-
up to evaluate the efficacy of medical therapy.
US seems to be more useful in the biliary stage of
the disease. Irregular thickening of the common
bile duct wall and biliary dilation are the findings
visualised by abdominal CT and US that are
suspicious for fascioliasis [8,9]. Adult flukes
promote hyperplasia and hypertrophy of the
duct epithelium, resulting in thickening of the
duct walls and periductal fibrosis [10]. In chronic
fasciolasis, abdominal US results may be either
normal or may show mobile vermiform struc-
tures without acoustic shadowing within the gall
bladder and in the bile ducts, representing flukes
that may be confused with stones [11,12]. CT
scans of the abdomen almost always show
abnormalities in patients with a suspected diag-
nosis of fascioliasis. After administration of con-
trast material, the abnormalities seen most
commonly on CT scans are multiple, small,
indiscrete, hypodense lesions 2–10 mm in diam-
eter, and microabscesses arranged in a tunnel-like
branching pattern, with frequent subcapsular
locations of the lesions. In rare instances,
abscess-like lesions 7–10 cm in diameter can be
seen. Liver capsular thickening and subcapsular
haemorrhage can also be detected [11,12]. Mag-
netic resonance imaging provides similar find-
ings, which are suggestive of various changes
associated with traumatic hepatitis caused by the
migration of the fluke in the liver [13]. Invasive
techniques, such as percutaneous cholangiogra-
phy and endoscopic retrograde cholangiography,
can reveal some abnormalities, but are generally
not required for the diagnosis [14,15]. Liver
biopsy is not usually indicated, but if it is
performed, necrotic debris, track-like destruction
of parenchyma, polymorphonuclear infiltration
with abundant eosinophils, Charcot–Lyden crys-
tals, granulomas with or without eggs, fibrosis
and bile duct proliferation are the classical
findings from the biopsy specimens [16].
Although praziquantel is the drug of choice for
other trematodes, this agent is ineffective against
F. hepatica. The CDC recommends triclabendazole
as the first-line agent for the treatment of F.
hepatica infection. Dizziness, headache, fever and
abdominal pain 5–6 days after the initiation of
treatment are the side-effects encountered most
commonly [17]. Bithionol is an alternative drug for
the treatment of F. hepatica infection. Cure rates of
up to 100% have been reported with three divided
doses on alternate days, with the disadvantage of
frequent side-effects, including nausea, vomiting,
pruritus, urticaria, abdominal colic and rash [18].
The main difficulty with F. hepatica infection is
the delay in arriving at a diagnosis, particularly in
Western countries, despite the fact that large
outbreaks have been reported from different parts
of the world [19]. When a patient presents with
abdominal pain and fever, serology for F. hepatica
should be obligatory if elevated liver enzymes
and eosinophilia accompany hypodense lesions
with irregular margins on the CT scan. CT is very
helpful in obtaining a clear-cut diagnosis of the
disease and in distinguishing fascioliasis from
other causes. Although the world is becoming
more developed, natural disasters still occur on a
regular basis. Contaminated water and water
plants are the potential sources of F. hepatica
infection. In such circumstances, every effort
should be made to exclude the possibility of F.
hepatica infection, which is not just an historical
problem, but remains a disease of the modern
world.
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